Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + atezolizumab versus second novel hormonal therapy in metastatic castration-resistant prostate cancer
jRCT2011200005Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cabozantinib, atezolizumab, abiraterone, prednisone and enzalutamide in prostate adenocarcinoma and prostate cancer (PCa) (2 arms), sponsored by Takeda. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
cabozantinibatezolizumababirateroneprednisoneenzalutamide
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2011200005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200005.